Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma

NCT00017433 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00017433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2001
Completion date
January 31, 2005
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm